Post Polio Syndrome News and Research

RSS

Home non-invasive ventilation for COPD: an interview with Dr Holger Woehrle

The key symptom of COPD is breathlessness, especially during daily activity, and the breathlessness is in addition to cough and chest tightness. The difficulty in managing this disease is that it's a disease that progresses with age.

From ResMed Corp 18 Oct 2016

tDCS for 15 days improves sleep and fatigue symptoms in patients with PPS

Of the 15 million people around the world who have survived poliomyelitis, up to 80% report progressive deteriorating strength and endurance many years after infection, a condition known as post-polio syndrome (PPS).

27 Aug 2013

New book explores experiences of polio victims alongside medical, scientific landmarks

Thanks to vaccination, polio has been pushed to the brink of extinction - but can we finish the job? This is one of the big questions which a Bristol academic addresses in his new book, published next week.

20 Jun 2013

Diffusion tensor imaging detects complex muscle structures in 3D

Eindhoven University of Technology (TU/e) and the Academic Medical Center (AMC) in Amsterdam have together developed a technique that allows detailed 3D imaging of complex muscle structures of patients.

31 Oct 2012

Antibody that neutralizes enzyme Kallikrein 6 staves off MS

Researchers studying multiple sclerosis(MS) have long been looking for the specific molecules in the body that cause lesions in myelin, the fatty, insulating cells that sheathe the nerves.

30 Apr 2012

Salk Institute uncovers presenilin's productive side

Mutant presenilin is infamous for its role in the most aggressive form of Alzheimer's disease-early-onset familial Alzheimer's-which can strike people as early as their 30s. In their latest study, researchers at the Salk Institute uncovered presenilin's productive side: It helps embryonic motor neurons navigate the maze of chemical cues that pull, push and hem them in on their way to their proper targets.

19 Jan 2011

Grifols to acquire Pharmalink's Xepol programme for post-polio syndrome

Pharmalink AB, today announced that it has closed its agreement with Grifols SA for the acquisition of Pharmalink's Xepol(R) programme for the treatment of post-polio syndrome (PPS). The parties had previously announced reaching an agreement whereby Grifols would acquire all know-how and global intellectual property rights related to the use of human immunoglobulin for the treatment of (PPS) - the concept at the heart of the Xepol programme.

30 Jun 2010

Grifols reaches agreement with Pharmalink to acquire PPS drug development project

Today, Grifols SA announced that it has reached an agreement with the Swedish company Pharmalink AB to acquire various forms of intellectual property associated with the treatment of post-polio syndrome. The acquisition is expected to be finalized in the next few weeks and will include documentation, know-how, and Swedish regulatory approvals under the trade name Xepol.

20 May 2010